Optimal assessment of response in ovarian cancer

21Citations
Citations of this article
59Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objective tumor response and progression, measured by standard criteria such as RECIST 1.1, are important measures of change in tumor size that are utilized as endpoints in phase II and III clinical trials. In ovarian cancer, RECIST criteria, which are based on anatomical tumor size, have been supplemented by CA125 response and progression criteria developed by the Gynecologic Cancer InterGroup. CA125 progression has been integrated with objective criteria into a composite definition ofprogression often used in the front-line setting, whereas response criteria are generally intended for use in recurrent disease trials. In terms of the performance of these endpoints in clinical trials, objective response, when used to assess the activity of new drugs in phase II trials in recurrent ovarian cancer, has proven tobe helpful in identifying agents that have subsequently been shown to improve overall or progression-free survival in randomized trials. Thus, objective response hasutility as an endpoint for new drug screening trials. Progression-free survival is often used as the primary (or co-primary) efficacy endpoint in studies of first-line therapy in ovarian cancer. Data from historical studies of platinum-based chemotherapy regimens indicate that improvements in progression-free survival generally translate into overall survival gains, indicating it may qualify as a surrogate endpoint for overall survival. It is not yet clear if this relationship will hold true in randomized trials of targeted agents, making it important to continue to assess overall survival in such studies. Finally, the routine monitoring of CA125 inpatients after completion of front-line treatment as part of the standard of care has come under question with the publication of the results of a large European study;therefore, the use of CA125 progression as an endpoint in clinical trials will also likely be debated in the coming years.©The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Cite

CITATION STYLE

APA

Eisenhauer, E. A. (2011). Optimal assessment of response in ovarian cancer. In Annals of Oncology (Vol. 22, pp. 49–51). Oxford University Press. https://doi.org/10.1093/annonc/mdr467

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free